AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States

AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States

TAIPEI, March 27, 2025 /PRNewswire/ -- AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), has officially entered Phase I...

menu
menu